Cerner (NASDAQ:CERN)‘s stock had its “buy” rating reiterated by stock analysts at Cantor Fitzgerald in a report released on Wednesday, March 14th. They currently have a $80.00 price objective on the stock. Cantor Fitzgerald’s price objective indicates a potential upside of 41.79% from the stock’s current price.
The analysts wrote, “Various news outlets are suggesting that President Trump will soon replace VA Secretary David Shulkin.””
Other research analysts also recently issued reports about the stock. Zacks Investment Research raised shares of Cerner from a “hold” rating to a “buy” rating and set a $79.00 price target on the stock in a research note on Tuesday, January 9th. Robert W. Baird reissued a “buy” rating on shares of Cerner in a research note on Wednesday, January 3rd. Royal Bank of Canada reissued a “buy” rating and set a $74.00 price target on shares of Cerner in a research note on Wednesday, November 22nd. Piper Jaffray reissued a “buy” rating and set a $70.00 price target on shares of Cerner in a research note on Wednesday, November 22nd. Finally, Canaccord Genuity reissued a “buy” rating on shares of Cerner in a research note on Wednesday, February 7th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating and ten have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $67.42.
Shares of CERN stock traded down $1.70 during trading hours on Wednesday, hitting $56.42. 2,983,674 shares of the company’s stock were exchanged, compared to its average volume of 3,355,942. The company has a market capitalization of $18,765.12, a PE ratio of 25.65, a price-to-earnings-growth ratio of 1.64 and a beta of 0.96. Cerner has a 12-month low of $55.29 and a 12-month high of $73.86. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.99 and a current ratio of 3.01.
Cerner (NASDAQ:CERN) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $0.58 EPS for the quarter, missing the consensus estimate of $0.61 by ($0.03). The business had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.33 billion. Cerner had a return on equity of 16.82% and a net margin of 16.86%. The company’s revenue was up 4.5% compared to the same quarter last year. During the same period last year, the business posted $0.61 earnings per share. research analysts predict that Cerner will post 2.42 EPS for the current year.
In related news, Vice Chairman Clifford W. Illig sold 307,700 shares of Cerner stock in a transaction on Thursday, March 8th. The shares were sold at an average price of $64.52, for a total value of $19,852,804.00. Following the sale, the insider now owns 1,229,719 shares in the company, valued at $79,341,469.88. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director William D. Zollars sold 4,100 shares of Cerner stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $62.16, for a total transaction of $254,856.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 541,800 shares of company stock worth $34,353,860. 13.11% of the stock is currently owned by company insiders.
Large investors have recently added to or reduced their stakes in the stock. Icon Wealth Partners LLC bought a new stake in Cerner in the fourth quarter valued at $107,000. Fuller & Thaler Asset Management Inc. bought a new stake in shares of Cerner during the 3rd quarter valued at $121,000. Steward Partners Investment Advisory LLC bought a new stake in shares of Cerner during the 3rd quarter valued at $128,000. Cerebellum GP LLC bought a new stake in shares of Cerner during the 4th quarter valued at $127,000. Finally, Delpha Capital Management LLC bought a new stake in shares of Cerner during the 4th quarter valued at $144,000. Institutional investors and hedge funds own 78.54% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Cerner (NASDAQ:CERN) Rating Reiterated by Cantor Fitzgerald” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/08/cerner-cern-earns-buy-rating-from-cantor-fitzgerald.html.
Cerner Corporation provides health care information technology solutions and services in the United States and internationally. The company offers Cerner Millennium architecture, a person-centric computing framework, which includes clinical, financial, and management information systems that allow providers to access an individual's electronic health record (EHR) at the point of care, and organizes and delivers information for physicians, nurses, laboratory technicians, pharmacists, front- and back-office professionals, and consumers.
Receive News & Ratings for Cerner Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerner and related companies with MarketBeat.com's FREE daily email newsletter.